A Phase 3 interventional study of Product 33525 in Tinea Pedis, Tinea Cruris and Tinea Corporis, sponsored by Tinea Pharmaceuticals. Completed at 24 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-01-23.
Sponsored by Tinea Pharmaceuticals · Phase 3 and Interventional
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.
73 studies on the registry are indexed under Tinea Pedis; 8 are open to participants now.
This study's enrollment of 604 is above the median of 128 across 66 interventional studies indexed under Tinea Pedis.
Browse Tinea Pedis studies →Tinea Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Product 33525
Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
Number of Subjects with Adverse Events
To examine the long-term safety of treating tinea pedis, tinea corporis or tinea cruris, treatment-emergent adverse events occurring during the study will be recorded. Adverse events will be summarized by the number of subjects reporting events, system organ class, preferred term, severity, relationship to study drug, and seriousness. Baseline and end of study laboratory assessments will be conducted.
Time frame: One Year
Clinical Cure and Mycological Cure
Proportion of patients achieving effective treatment
Time frame: 1 week Post Treatment, 2 weeks Post Treatment, and 3 weeks Post Treatment
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tinea Pharmaceuticals